Relapse-onset MS patients have a substantially reduced risk of contrast-enhancing lesions or new T2 lesions after they reach age 50 years, according to a longitudinal analysis of the Amsterdam MS cohort study (Coerver et al. Eur J Neurol 2023;30:2385-2392). Read More
Neurology
EAN HIGHLIGHTS 2023 – WEDNESDAY, JULY 5 EDITION
July 5, 2023Selected highlights from the European Academy of Neurology annual meeting, Budapest, Hungary, July 1-4, 2023.
Ofatumumab – 5-year efficacy data
MS influenced by prior pregnancies
NfL not useful to predict cognitive impairment
Improved outcome with autoimmune comorbidity in MS
Clinical tip of the day Read More
EAN HIGHLIGHTS 2023 – TUESDAY, JULY 4 EDITION
July 4, 2023Selected highlights from the European Academy of Neurology annual meeting, Budapest, Hungary, July 1-4, 2023.
Update on BTK inhibitors
Adding OCT to the McDonald criteria
How does cognitive impairment progress?
Clinical tip of the day Read More
EAN HIGHLIGHTS 2023 – MONDAY, JULY 3 EDITION
July 3, 2023Selected highlights from the European Academy of Neurology annual meeting, Budapest, Hungary, July 1-4, 2023.
Few patients achieve an optimal response with platform therapies
Fluid biomarkers predict early disease activity
When does PIRA start?
MOG antibodies uncommon
Clinical tip of the day Read More
NEUROLOGY NEWS IN BRIEF – JUNE 2023
June 27, 2023The following is a quick summary of interesting reports in the literature for June 2023.
COVID-19
CNS infection
Alzheimer’s disease
Biomarkers
Headache
Multiple sclerosis
Neurodegenerative disorders
Neuromyelitis optica
Stroke Read More